Foghorn Therapeutics Stock Analysis
| FHTX Stock | USD 7.79 0.27 3.59% |
Foghorn Therapeutics is undervalued with Real Value of 9.42 and Target Price of 15.25. The main objective of Foghorn Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Foghorn Therapeutics is worth, separate from its market price. There are two main types of Foghorn Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Foghorn Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Foghorn Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Foghorn Stock trading window is adjusted to America/New York timezone.
Foghorn |
Foghorn Stock Analysis Notes
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.92. Foghorn Therapeutics had not issued any dividends in recent years. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To learn more about Foghorn Therapeutics call Adrian Gottschalk at 617 586 3100 or check out https://foghorntx.com.Foghorn Therapeutics Investment Alerts
| Foghorn Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (86.39 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Wall Street Analysts See a 104.08 percent Upside in Foghorn Therapeutics Can the Stock Really Move This High |
Foghorn Therapeutics Upcoming and Recent Events
Earnings reports are used by Foghorn Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Foghorn Largest EPS Surprises
Earnings surprises can significantly impact Foghorn Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-09 | 2022-12-31 | -0.62 | -0.69 | -0.07 | 11 | ||
2022-08-09 | 2022-06-30 | -0.59 | -0.66 | -0.07 | 11 | ||
2024-10-31 | 2024-09-30 | -0.44 | -0.31 | 0.13 | 29 |
Foghorn Therapeutics Environmental, Social, and Governance (ESG) Scores
Foghorn Therapeutics' ESG score is a quantitative measure that evaluates Foghorn Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Foghorn Therapeutics' operations that may have significant financial implications and affect Foghorn Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Foghorn Stock Institutional Investors
| Shares | Alphabet Inc | 2024-09-30 | 500.9 K | State Street Corp | 2024-06-30 | 482.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 399.7 K | Birchview Capital, Lp | 2024-09-30 | 320.9 K | Northern Trust Corp | 2024-09-30 | 250.8 K | The Colony Group Llc | 2024-06-30 | 215.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 130.2 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 129.3 K | Sio Capital Management, Llc | 2024-09-30 | 121.7 K | Flagship Ventures Management, Inc. | 2024-06-30 | 12.7 M | Fmr Inc | 2024-09-30 | 6.3 M |
Foghorn Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 433.07 M.Foghorn Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.47) | (0.50) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | 1.28 | 1.34 |
Management Efficiency
Foghorn Therapeutics has return on total asset (ROA) of (0.2045) % which means that it has lost $0.2045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn Therapeutics' management efficiency ratios could be used to measure how well Foghorn Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.34 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Foghorn Therapeutics' Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to rise to 0.13 in 2024, whereas Total Assets are likely to drop slightly above 280.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.84) | (1.75) | |
| Tangible Book Value Per Share | (1.84) | (1.75) | |
| Enterprise Value Over EBITDA | (2.25) | (2.37) | |
| Price Book Value Ratio | (3.51) | (3.33) | |
| Enterprise Value Multiple | (2.25) | (2.37) | |
| Price Fair Value | (3.51) | (3.33) | |
| Enterprise Value | 235.5 M | 223.7 M |
Understanding the operational decisions made by Foghorn Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin (3.05) | Beta 3.148 | Return On Assets (0.20) | Return On Equity (4.70) |
Technical Drivers
As of the 28th of November, Foghorn Therapeutics shows the Mean Deviation of 3.94, coefficient of variation of 5116.47, and Downside Deviation of 4.5. Foghorn Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Foghorn Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Foghorn Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Foghorn Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Foghorn Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Foghorn Therapeutics Outstanding Bonds
Foghorn Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Foghorn Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Foghorn bonds can be classified according to their maturity, which is the date when Foghorn Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Foghorn Therapeutics Predictive Daily Indicators
Foghorn Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Foghorn Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Foghorn Therapeutics Corporate Filings
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 10th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 20th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 18th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 4th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Foghorn Therapeutics Forecast Models
Foghorn Therapeutics' time-series forecasting models are one of many Foghorn Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Foghorn Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Foghorn Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Foghorn Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Foghorn shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Foghorn Therapeutics. By using and applying Foghorn Stock analysis, traders can create a robust methodology for identifying Foghorn entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (2.76) | (2.90) | |
| Operating Profit Margin | (3.16) | (3.32) | |
| Net Loss | (2.88) | (3.03) | |
| Gross Profit Margin | (2.21) | (2.32) |
Current Foghorn Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Foghorn analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Foghorn analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 15.25 | Strong Buy | 7 | Odds |
Most Foghorn analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Foghorn stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Foghorn Therapeutics, talking to its executives and customers, or listening to Foghorn conference calls.
Foghorn Stock Analysis Indicators
Foghorn Therapeutics stock analysis indicators help investors evaluate how Foghorn Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Foghorn Therapeutics shares will generate the highest return on investment. By understating and applying Foghorn Therapeutics stock analysis, traders can identify Foghorn Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 53.9 M | |
| Common Stock Shares Outstanding | 42 M | |
| Total Stockholder Equity | -77.2 M | |
| Tax Provision | 4.2 M | |
| Property Plant And Equipment Net | 42.9 M | |
| Cash And Short Term Investments | 234.1 M | |
| Cash | 80.3 M | |
| Accounts Payable | 6.3 M | |
| Net Debt | -35.3 M | |
| 50 Day M A | 8.2972 | |
| Total Current Liabilities | 58.4 M | |
| Other Operating Expenses | 142.1 M | |
| Non Current Assets Total | 45.7 M | |
| Non Currrent Assets Other | 2.8 M | |
| Stock Based Compensation | 16.2 M |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.